Recommended Temozolomide (Temodar) Dosing
The recommended temozolomide dose depends on the clinical indication: for newly diagnosed glioblastoma, use 75 mg/m² daily during concurrent radiotherapy followed by 150-200 mg/m² for 5 days every 28 days for maintenance; for refractory anaplastic astrocytoma, start at 150 mg/m² daily for 5 days every 28 days, escalating to 200 mg/m² if tolerated. 1
Newly Diagnosed Glioblastoma (Standard Stupp Protocol)
The 2022 ASCO-SNO guidelines provide clear dosing recommendations based on the landmark EORTC 26981-22981 trial 2:
Concurrent Phase (with Radiation)
- Dose: 75 mg/m² once daily
- Duration: Throughout radiotherapy (42 days with standard 60 Gy radiation)
- Can extend: Up to 49 days if blood counts adequate (ANC ≥1.5 × 10⁹/L, platelets ≥100 × 10⁹/L)
- No dose reductions during concurrent phase; only dose interruptions for toxicity 1
Maintenance Phase (Starting 4 Weeks Post-Radiation)
- Cycle 1: 150 mg/m² daily for 5 consecutive days, then 23 days rest
- Cycles 2-6: Escalate to 200 mg/m² daily for 5 days if Cycle 1 tolerated (non-hematologic toxicity ≤Grade 2, ANC ≥1.5 × 10⁹/L, platelets ≥100 × 10⁹/L)
- Total duration: Maximum 6 cycles 2, 1
Critical caveat: If dose not escalated at Cycle 2, do not escalate in subsequent cycles 1. Recent evidence confirms that actual body weight dosing (not adjusted/capped dosing) correlates with improved survival—doses ≥97.8% of calculated BSA showed 0.3 years longer median OS 3.
Hypofractionated Regimen (Elderly/Poor Performance Status)
For patients where standard 6-week radiation may not outweigh harms 2:
Concurrent Phase
- Dose: 75 mg/m² daily for 21 days (with 40.05 Gy in 15 fractions)
Maintenance Phase
- Dose: 150-200 mg/m² daily for 5 of 28 days
- Duration: Maximum 12 months (longer than standard protocol) 2
Refractory Anaplastic Astrocytoma
Per FDA labeling and guidelines 1:
- Initial dose: 150 mg/m² daily for 5 consecutive days per 28-day cycle
- Escalation: Increase to 200 mg/m² if nadir and Day 29 counts adequate (ANC ≥1.5 × 10⁹/L, platelets ≥100 × 10⁹/L)
- Dose reduction: Decrease by 50 mg/m² (minimum 100 mg/m²) if ANC <1.0 × 10⁹/L or platelets <50 × 10⁹/L
- Duration: Continue until progression or unacceptable toxicity
IDH-Mutant Gliomas
For IDH-mutant astrocytomas (grades 2-3) and oligodendrogliomas 2:
- Adjuvant dose: 150-200 mg/m² daily for days 1-5 every 4 weeks
- Duration: Maximum 12 months
- This applies to both 1p19q codeleted and non-codeleted tumors when temozolomide is chosen over PCV
Alternative Regimens (Not Standard)
The EANO 2021 guidelines mention temozolomide monotherapy for elderly patients with MGMT-methylated tumors 4:
- Option 1: 200 mg/m² days 1-5 every 28 days for up to 6 cycles
- Option 2: 100 mg/m² days 1-7 every 2 weeks until progression
However, these are alternatives to combined chemoradiation, not the preferred approach for fit patients.
Monitoring Requirements
During concurrent phase: Weekly CBC 1
During maintenance: CBC on Day 22 (or within 48 hours) and weekly until ANC >1.5 × 10⁹/L and platelets >100 × 10⁹/L 1
Do not start next cycle until blood counts recover to threshold values.
Important Pitfalls to Avoid
Underdosing: Rounding down significantly from calculated BSA dose may compromise efficacy—aim for ≥97.8% of calculated dose 3. However, a 2025 study suggests rounding to reduce pill burden doesn't significantly impact survival 5, though this conflicts with earlier data.
PCP prophylaxis: Required during concurrent chemoradiation and continued if lymphocytopenia develops 1
Premature escalation: Only escalate maintenance dose at Cycle 2 if Cycle 1 tolerated; never escalate later 1
Extended duration confusion: Standard glioblastoma maintenance is 6 cycles; hypofractionated regimen allows up to 12 months 2
MGMT status: While MGMT methylation predicts better temozolomide response, current guidelines recommend temozolomide for all newly diagnosed glioblastoma patients regardless of MGMT status 4